Leveraging insights from OpenAI’s ChatGPT, Finbold has curated a $1,000 stock portfolio designed to capture growth ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...